Evidence map›Paper›PMID 32143690›Full record

ArticleStem cell research & therapy2020

Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia.

Lucia Beltran-Camacho, Margarita Jimenez-Palomares, Marta Rojas-Torres, Ismael Sanchez-Gomar, Antonio Rosal-Vela, Sara Eslava-Alcon, Mª Carmen Perez-Segura, Ana Serrano, Borja Antequera-González, Jose Angel Alonso-Piñero and 6 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Lucia Beltran-CamachoBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Margarita Jimenez-PalomaresBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Marta Rojas-TorresBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Ismael Sanchez-GomarBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Antonio Rosal-VelaBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Sara Eslava-AlconBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Mª Carmen Perez-SeguraBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Ana SerranoBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Borja Antequera-GonzálezBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Jose Angel Alonso-PiñeroBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Almudena González-RoviraBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Mª Jesús Extremera-GarcíaBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
Manuel Rodriguez-PiñeroAngiology & Vascular Surgery Unit, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Rafael Moreno-LunaLaboratory of Neuroinflammation, Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain.
Martin Røssel LarsenDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Mª Carmen Durán-RuizBiomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain. maricarmen.duran@gm.uca.es.ORCID 0000-0002-1700-0141
Universidad de Cádiz · ESHospital Universitario Puerta del Mar · ESServicio de Salud de Castilla La Mancha · ESUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCritical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk of mortality due to associated comorbidities. Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical assays with CACs have shown promising results. A better understanding of how these cells participate in vascular regeneration would significantly help to potentiate their role in revascularization. Herein, we analyzed the initial molecular mechanisms triggered by human CACs after being administered to a murine model of CLI, in order to understand how these cells promote angiogenesis within the ischemic tissues.

methodsBalb-c nude mice (n:24) were distributed in four different groups: healthy controls (C, n:4), shams (SH, n:4), and ischemic mice (after femoral ligation) that received either 50 μl physiological serum (SC, n:8) or 5 × 10

resultsAdministration of CACs induced in the ischemic tissues an increase in the number of blood vessels as well as the diameter size compared to ischemic, non-treated mice, although the number of CACs decreased within time. The initial protein changes taking place in response to ischemia and more importantly, right after administration of CACs to CLI mice, are shown.

conclusionsOur results indicate that CACs migrate to the injured area; moreover, they trigger protein changes correlated with cell migration, cell death, angiogenesis, and arteriogenesis in the host. These changes indicate that CACs promote from the beginning an increase in the number of vessels as well as the development of an appropriate vascular network.

Indexed as

Neovascularization, PhysiologicPeripheral Arterial DiseaseAnimalsCell- and Tissue-Based TherapyHumansIschemiaMiceMice, NudeAngiogenesisArteriogenesisCirculating angiogenic cellsCritical limb ischemiaProteomics

Identifiers

PMID32143690
PMCPMC7060566
OpenAlexW3012371549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.